S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
PRI   90.71 (+0.83%)
DIS   99.80 (+3.53%)
S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
PRI   90.71 (+0.83%)
DIS   99.80 (+3.53%)
S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
PRI   90.71 (+0.83%)
DIS   99.80 (+3.53%)
S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
PRI   90.71 (+0.83%)
DIS   99.80 (+3.53%)
Log in

NASDAQ:ACIU - AC Immune Stock Price, Forecast & News

$7.30
+0.95 (+14.96 %)
(As of 03/30/2020 04:00 PM ET)
Today's Range
$6.39
Now: $7.30
$7.30
50-Day Range
$4.24
MA: $6.99
$9.55
52-Week Range
$4.07
Now: $7.30
$10.14
Volume217,534 shs
Average Volume169,569 shs
Market Capitalization$493.20 million
P/E Ratio10.43
Dividend YieldN/A
Beta0.74
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company's lead product candidate is crenezumab, a humanized, monoclonal, and conformation-specific anti-Abeta antibody, which is in Phase III clinical studies for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase I/IIa clinical study for AD; and ACI-35, an anti-Tau vaccine candidate against phosphorylated pathological tau and is in Phase Ib clinical testing in patients with mild to moderate AD, as well as RO7105705, an anti-Tau monoclonal antibody candidate, which is in Phase II clinical study for AD patients. In addition, the company has discovery and pre-clinical stage molecules targeting neurodegenerative diseases, as well as diagnostics targeting Tau, alpha-synuclein, and TDP-43 aggregates. It has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Piramal Imaging; Eli Lilly and Company; Essex Bio-Technology Limited; and WuXi Biologics, as well as Nestlé Institute of Health Sciences. AC Immune SA was founded in 2003 and is headquartered in Lausanne, Switzerland.
Read More
AC Immune logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ACIU
CUSIPN/A
Phone41-21-345-9121

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$7.36 million
Book Value$2.76 per share

Profitability

Net Income$-52,090,000.00

Miscellaneous

Employees92
Market Cap$493.20 million
Next Earnings Date4/2/2020 (Estimated)
OptionableNot Optionable

Receive ACIU News and Ratings via Email

Sign-up to receive the latest news and ratings for ACIU and its competitors with MarketBeat's FREE daily newsletter.


AC Immune (NASDAQ:ACIU) Frequently Asked Questions

How has AC Immune's stock been impacted by COVID-19 (Coronavirus)?

AC Immune's stock was trading at $5.49 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ACIU shares have increased by 33.0% and is now trading at $7.30. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of AC Immune?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AC Immune in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for AC Immune.

When is AC Immune's next earnings date?

AC Immune is scheduled to release its next quarterly earnings announcement on Thursday, April 2nd 2020. View our earnings forecast for AC Immune.

How were AC Immune's earnings last quarter?

AC Immune SA (NASDAQ:ACIU) posted its earnings results on Wednesday, November, 13th. The company reported $0.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.17 by $0.08. The business earned $33.90 million during the quarter, compared to analysts' expectations of $31.50 million. AC Immune had a return on equity of 19.18% and a net margin of 45.19%. View AC Immune's earnings history.

What price target have analysts set for ACIU?

1 Wall Street analysts have issued 12-month price objectives for AC Immune's shares. Their forecasts range from $11.00 to $11.00. On average, they anticipate AC Immune's stock price to reach $11.00 in the next year. This suggests a possible upside of 50.7% from the stock's current price. View analysts' price targets for AC Immune.

Has AC Immune been receiving favorable news coverage?

Media coverage about ACIU stock has trended very negative this week, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. AC Immune earned a media sentiment score of -3.3 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutAC Immune.

Are investors shorting AC Immune?

AC Immune saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 365,000 shares, an increase of 18.0% from the February 13th total of 309,200 shares. Based on an average daily volume of 159,000 shares, the days-to-cover ratio is currently 2.3 days. Approximately 1.1% of the shares of the company are sold short. View AC Immune's Current Options Chain.

Who are some of AC Immune's key competitors?

What other stocks do shareholders of AC Immune own?

Who are AC Immune's key executives?

AC Immune's management team includes the following people:
  • Dr. Andrea Pfeifer, Co-Founder, CEO & Director (Age 61)
  • Mr. Joerg Hornstein, Chief Financial Officer (Age 41)
  • Mr. Piergiorgio Donati, Head of Technical Operations & Program Management (Age 48)
  • Dr. Marie Kosco-Vilbois, Chief Scientific Officer (Age 61)
  • Mr. Jean-Fabien Monin, Chief Admin. Officer (Age 48)

When did AC Immune IPO?

(ACIU) raised $55 million in an IPO on Friday, September 23rd 2016. The company issued 4,600,000 shares at a price of $11.00-$13.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO.

What is AC Immune's stock symbol?

AC Immune trades on the NASDAQ under the ticker symbol "ACIU."

Who are AC Immune's major shareholders?

AC Immune's stock is owned by many different retail and institutional investors. Top institutional shareholders include BVF Inc. IL (16.79%), Renaissance Technologies LLC (0.72%), Acadian Asset Management LLC (0.48%), Marshall Wace LLP (0.20%), FMR LLC (0.10%) and Alpine Woods Capital Investors LLC (0.06%).

Which institutional investors are selling AC Immune stock?

ACIU stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Geode Capital Management LLC, Marshall Wace North America L.P., Tower Research Capital LLC TRC, and ProShare Advisors LLC.

Which institutional investors are buying AC Immune stock?

ACIU stock was bought by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Renaissance Technologies LLC, Marshall Wace LLP, BVF Inc. IL, Alpine Woods Capital Investors LLC, Oxford Asset Management LLP, Trexquant Investment LP, and Spark Investment Management LLC.

How do I buy shares of AC Immune?

Shares of ACIU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is AC Immune's stock price today?

One share of ACIU stock can currently be purchased for approximately $7.30.

How big of a company is AC Immune?

AC Immune has a market capitalization of $493.20 million and generates $7.36 million in revenue each year. The company earns $-52,090,000.00 in net income (profit) each year or ($0.82) on an earnings per share basis. AC Immune employs 92 workers across the globe. View additional information about AC Immune.

What is AC Immune's official website?

The official website for AC Immune is http://www.acimmune.com/.

How can I contact AC Immune?

AC Immune's mailing address is EPFL Innovation Park Building B, Lausanne V8, 1015. The company can be reached via phone at 41-21-345-9121 or via email at [email protected]


MarketBeat Community Rating for AC Immune (NASDAQ ACIU)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  228 (Vote Outperform)
Underperform Votes:  232 (Vote Underperform)
Total Votes:  460
MarketBeat's community ratings are surveys of what our community members think about AC Immune and other stocks. Vote "Outperform" if you believe ACIU will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACIU will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel